Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Trader J's Inner Circle -- Ignore unavailable to you. Want to Upgrade?

To: Trader J who wrote (5795)	1/24/1999 2:28:00 AM
From: thumbelina	Read Replies (2) \| Respond to of 56535

TJ - Wise words to heed - thanks. BTW - Your 21" monitor sounds interesting I am in the process of evaluating a 2nd PC & wondering if it's worth waiting for the Pentium III to come out as I'm also expecting cable modem to come out in a few months in my area (thought I'd get the 2nd PC when I can get high speed access as well). Anyway the 21" - is it a flat panel display? - haven't been able to find out if they make flat panel displays that large yet. Thanks again, Caroline

To: Trader J who wrote (5795)	1/24/1999 7:57:00 AM
From: ArtAlley	Respond to of 56535

ASCT buy-out question? Does anyone know the per share value of the two new drugs that will be coming out? It seems that preliminary approval has already been granted for these two drugs...but, what are they worth in a buy-out? How many millions(billions) per drug? We could be looking at a much more SPECTACULAR per share price increase than I had previously imagined! I am not trying to 'hype'...but, I can seriously see why this has taken some time...and might continue to take some more time. I did see $20 per share mentioned on another board even if there is no buy-out. This is getting interesting. Here is an old posting from their website on the two drugs and the distinct possiblity of approval. Nice website! Any CHEMISTRY majors out there? Ascent Pediatrics Receives FDA Comments on Primsol NDA Application Wilmington, MA - September 25, 1998 -- Ascent Pediatrics, Inc. (NASDAQ: ASCT), today announced at the SG Cowen Healthcare Conference in San Francisco, California that it received minor chemistry comments from the FDA on its NDA application for its lead antibiotic product, Primsol(r). In the comment letter, the FDA stated that it would accept a proposed new formulation of Primsol without requiring Ascent to conduct additional clinical trials. Based on this comment letter, Ascent believes that it will be able to obtain approval of its Primsol NDA application from the FDA in mid-1999. Dr. Emmett Clemente, Chairman and Founder of Ascent, stated, "We are very encouraged by this comment letter from the FDA and expect to be able to achieve mid-1999 approval of Primsol. We also believe that these comments provide useful guidance to us in pursuing approval of our ANDA application for Orapred, our second lead product, with the FDA." Alan R. Fox, President and CEO of Ascent, also present at the SG Cowen Healthcare Conference, stated, "In addition to Primsol and Orapred, we are also pursuing co-promotional arrangements with third parties. Earlier this year we concluded an important co-promotional agreement with Bristol-Myers Squibb for Duricef Oral Suspension. Our strategy is to increase Ascent's revenues through co-promotional agreements until our own products are approved by the FDA. We expect to conclude at least one new agreement before the end of this year." Ascent Pediatrics, Inc. is a drug development and marketing company focused exclusively on the pediatric market. The Company's strategy is to address the unmet needs of children through the development of differentiated, proprietary products based on approved compounds with well known clinical profiles. Ascent is developing a range of pharmaceuticals designed to improve upon currently available products for common pediatric illness through the application of its delivery and reformulation techniques.